ChemoCentryx Jumped by 348%. Is It a Buy?
Positive trial results are always a good thing, but is this newly hyped stock worth it?
ChemoCentryx
CCXI
CCXI
$40.74
-$1.78
-4.2%
BATS BZX Real Time Price as of January 23, 2020, 4:30 p.m. EST
View Interactive CCXI Charts
Chemocentryx Inc. is a biopharmaceutical company focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer.
News & Analysis: ChemoCentryx
Here's Why ChemoCentryx Skyrocketed 278% Today
The company unveiled positive data for the most advanced drug in its pipeline.
Why Nutanix, Dick's Sporting Goods, and ChemoCentryx Jumped Today
Find out how three stocks in very different sectors all posted solid gains.
ChemoCentryx Inc (CCXI) Q3 2019 Earnings Call Transcript
CCXI earnings call for the period ending September 30, 2019.
Is This Small-Cap Biotech a Buy Before 2020?
Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.
ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript
CCXI earnings call for the period ending June 30, 2019.
Why ChemoCentryx Shares Crashed 19.1% Today
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript
CCXI earnings call for the period ending March 31, 2019.
ChemoCentryx (CCXI) Q4 2018 Earnings Conference Call Transcript
CCXI earnings call for the period ending December 31, 2018.
ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript
CCXI earnings call for the period ending December 31, 2017
